Close Menu

multiplex assays

NEW YORK (GenomeWeb) — Transgenomic said today that it has signed a licensing deal with the Dana-Farber Cancer Institute for exclusive worldwide rights to develop and commercialize multiplexed versions of its ICE COLD-PCR technology.

NEW YORK (GenomeWeb) – Aushon Biosystems has been building up its IP portfolio ahead of a planned expansion to its Cira immunoassay platform.

NEW YORK (GenomeWeb News) – PrimeraDx said that it has received US Food and Drug Administration 510(k) clearance for its ICEPlex System and ICEPlex C. difficile Assay Kit.

NEW YORK (GenomeWeb News) – Toronto-based life sciences and diagnostics company SQI Diagnostics today announced a method development deal with Isis Pharmaceuticals.

NEW YORK (GenomeWeb News) – The National Cancer Institute has awarded Genalyte a $1 million Small Business Innovation Research grant to develop a biomarker panel to profile tumor antigen-associated antibodies, Genalyte said today.

NEW YORK (GenomeWeb News) – TB Biosciences, which is developing a point-of-care test for the detection of tuberculosis, said today it has closed on its Series A financing round, raising $1.5 million.
The financing will be used to support product development and clinical trials.

NEW YORK (GenomeWeb News) – Luminex said after the close of the market on Tuesday it has extended its global supply and distribution agreement with EMD Millipore.

NEW YORK (GenomeWeb News) – Stat-Diagnostica today announced that it has raised €17 million ($22.1 million) in a Series B financing round.

NEW YORK (GenomeWeb News) – PrimeraDx today announced a deal with Quest Diagnostics to co-develop molecular diagnostic products and services.
The focus of the non-exclusive deal is to support drug developers in the clinical development of targeted therapeutics.

NEW YORK (GenomeWeb News) – CyVek today said that it has raised $5.5 million in a Series D financing round.

Pages

The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.

The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.

Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.

In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.